

Siavosh Mahboobi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4206570/publications.pdf>

Version: 2024-02-01

51
papers

1,477
citations

279701

23
h-index

330025

37
g-index

55
all docs

55
docs citations

55
times ranked

2645
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. <i>Archives of Toxicology</i> , 2022, 96, 177-193.	1.9	10
2	A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. <i>Bioorganic Chemistry</i> , 2022, 119, 105505.	2.0	13
3	Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells. <i>Cell Chemical Biology</i> , 2022, 29, 398-411.e4.	2.5	9
4	A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia. <i>European Journal of Medicinal Chemistry</i> , 2020, 193, 112232.	2.6	8
5	Enantioselective synthesis and biological investigation of tetrahydro- β -carboline-based HDAC6 inhibitors with improved solubility. <i>Archiv Der Pharmazie</i> , 2019, 352, e1900026.	2.1	4
6	Human platelet lysate as validated replacement for animal serum to assess chemosensitivity. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2019, 36, 277-288.	0.9	12
7	Design and biological evaluation of tetrahydro- β -carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 152, 329-357.	2.6	34
8	Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3454-3477.	2.9	56
9	Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance. <i>Scientific Reports</i> , 2018, 8, 10039.	1.6	36
10	HSP90 is necessary for the ACK1-dependent phosphorylation of STAT1 and STAT3. <i>Cellular Signalling</i> , 2017, 39, 9-17.	1.7	32
11	Class I histone deacetylases regulate p53/NF- κ B crosstalk in cancer cells. <i>Cellular Signalling</i> , 2017, 29, 218-225.	1.7	41
12	Generation and Assessment of Fusions Between HDACi and TKi. <i>Methods in Molecular Biology</i> , 2017, 1510, 405-412.	0.4	6
13	Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells. <i>Archives of Toxicology</i> , 2017, 91, 2191-2208.	1.9	26
14	How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot. <i>Methods in Molecular Biology</i> , 2017, 1510, 355-364.	0.4	21
15	Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation. <i>Oncotarget</i> , 2017, 8, 26613-26624.	0.8	18
16	Concepts to Target MYC in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1792-1798.	1.9	64
17	Drugging the HDAC-HSP90 interplay in malignant cells. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 501-509.	4.0	110
18	Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases. <i>MedChemComm</i> , 2012, 3, 829.	3.5	28

#	ARTICLE	IF	CITATIONS
19	Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 125-136.	1.4	25
20	Chimeric tyrosine kinase-HDAC inhibitors as antiproliferative agents. <i>Anti-Cancer Drugs</i> , 2010, 21, 759-765.	0.7	6
21	Stent-based release of a selective PDGF-receptor blocker from the bis-indolylmethanon class inhibits restenosis in the rabbit animal model. <i>Vascular Pharmacology</i> , 2010, 52, 55-62.	1.0	15
22	Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 8546-8555.	2.9	87
23	Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3/ITD tyrosine kinase and partially overcome resistance to PKC412A <i>in vitro</i> . <i>British Journal of Haematology</i> , 2009, 144, 865-874.	1.2	11
24	Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-R ² , and Histone Deacetylases. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2265-2279.	2.9	83
25	2-Arylamino-4-Amino-5-Aroylthiazoles. <i>One-Pot Synthesis and Biological Evaluation of a New Class of Inhibitors of Tubulin Polymerization</i> . <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5551-5555.	2.9	53
26	Antibacterial activity of a novel series of 3-bromo-4-(1H-3-indolyl)-2,5-dihydro-1H-2,5-pyrroledione derivatives <i>–</i> An extended structure <i>–</i> activity relationship study. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 633-656.	2.6	16
27	Inhibition of PDGFR tyrosine kinase activity by a series of novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides <i>–</i> A SAR study on the bioisosterism of pyrimidine and imidazole. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 1444-1453.	2.6	8
28	2-Aroylindoles and 2-Aroylbenzofurans with N-Hydroxyacrylamide Substructures as a Novel Series of Rationally Designed Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 4405-4418.	2.9	56
29	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 2187-2197.	1.4	29
30	Novel Bis(1H-indol-2-yl)methanones as Potent Inhibitors of FLT3 and Platelet-Derived Growth Factor Receptor Tyrosine Kinase. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3101-3115.	2.9	46
31	[4-(Imidazol-1-yl)thiazol-2-yl]phenylamines. A Novel Class of Highly Potent Colchicine Site Binding Tubulin Inhibitors: Synthesis and Cytotoxic Activity on Selected Human Cancer Cell Lines. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5769-5776.	2.9	28
32	3-Bromo-4-(1H-3-indolyl)-2,5-dihydro-1H-2,5-pyrroledione derivatives as new lead compounds for antibacterially active substances. <i>European Journal of Medicinal Chemistry</i> , 2006, 41, 176-191.	2.6	41
33	Synthesis and cytotoxic activity of 2-acyl-1H-indole-4,7-diones on human cancer cell lines. <i>European Journal of Medicinal Chemistry</i> , 2005, 40, 85-92.	2.6	15
34	Synthesis and Cytotoxic Activity of 2-Acyl-1H-indole-4,7-diones on Human Cancer Cell Lines. <i>ChemInform</i> , 2005, 36, no.	0.1	0
35	Synthesis of Naturally Occurring Pyrazine and Imidazole Alkaloids from <i>Botryllus Leachi</i> ID=??, Dedicated to Prof. G. Märkl on the occasion of his 75 th birthday. <i>Monatshefte für Chemie</i> , 2004, 135, 333-342.	0.9	17
36	The tyrosine kinase FRK/RAK participates in cytokine-induced islet cell cytotoxicity. <i>Biochemical Journal</i> , 2004, 382, 261-268.	1.7	18

#	ARTICLE	IF	CITATIONS
37	A Single Amino Acid Exchange Inverts Susceptibility of Related Receptor Tyrosine Kinases for the ATP Site Inhibitor STI-571. <i>Journal of Biological Chemistry</i> , 2003, 278, 5148-5155.	1.6	58
38	Bis(1H-2-indolyl)methanones as a Novel Class of Inhibitors of the Platelet-Derived Growth Factor Receptor Kinase. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 1002-1018.	2.9	74
39	2-aryloindoles, a novel class of potent, orally active small molecule tubulin inhibitors. <i>Cancer Research</i> , 2002, 62, 3113-9.	0.4	36
40	Synthetic 2-Aryloindole Derivatives as a New Class of Potent Tubulin-Inhibitory, Antimitotic Agents. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 4535-4553.	2.9	103
41	Synthesis of bis(indolylmaleimide) macrocycles. <i>Journal of Heterocyclic Chemistry</i> , 2000, 37, 307-329.	1.4	7
42	Synthesis of pyrrolo[3,4-b]azepino[4,5,6-cd]indole-8,10-diones. <i>Journal of Heterocyclic Chemistry</i> , 2000, 37, 1177-1185.	1.4	6
43	Synthesis of the Racemates of the β -Carboline Alkaloid Chrysotricine and its Diastereomer. <i>Monatshefte für Chemie</i> , 2000, 131, 0383-0392.	0.9	6
44	Synthesis of Enantiomerically Pure (α)-(<i>S</i>)-Brevicolline. <i>Journal of Natural Products</i> , 1999, 62, 577-579.	1.5	15
45	Synthesis Of 2'-Amino-3'-Methoxyflavone (Pd 98059). <i>Synthetic Communications</i> , 1999, 29, 1645-1652.	1.1	5
46	Homoarcyriaflavin: Synthesis of Ring-Expanded Arcyriaflavin Analogues. <i>Journal of Organic Chemistry</i> , 1999, 64, 8130-8137.	1.7	29
47	Syntheses of (<i>RS</i>)- and (<i>S</i>)-(α)-Nazlinin and (<i>RS</i>)- and (+)-6-Azacyclodeca[5,4-b]indol-1-amine. <i>Archiv Der Pharmazie</i> , 1995, 328, 371-376.	2.1	10
48	Woodinine and its Stereomers - Absolute Configuration. <i>Archiv Der Pharmazie</i> , 1993, 326, 33-37.	2.1	5
49	Enantioselective Hydrosilylation and Hydrogenation of Alkaloid Precursors. <i>Archiv Der Pharmazie</i> , 1988, 321, 73-76.	2.1	17
50	Enantioselective Synthesis of Some Nicotiana Alkaloids. <i>Archiv Der Pharmazie</i> , 1988, 321, 175-177.	2.1	13
51	Preparation and GC-MS-Identification of N-Methyl- β -3-pyrroline. <i>Archiv Der Pharmazie</i> , 1988, 321, 423-424.	2.1	5